Robotic Vena Cava Thrombectomy with Three-dimensional Augmented Reality Guidance.

Augmented reality Caval thrombus Kidney cancer Robotic surgery Three-dimensional models

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Apr 2024
Historique:
accepted: 02 02 2024
medline: 4 3 2024
pubmed: 4 3 2024
entrez: 4 3 2024
Statut: epublish

Résumé

Robotic surgery has recently been used for treatment of renal cell carcinoma (RCC) and neoplastic thrombus located in the renal vein or inferior vena cava (IVC). Accurate identification of the thrombus location is crucial, and three-dimensional augmented reality (3D AR) may be valuable in achieving this. We enrolled patients with nonmetastatic RCC and level 0-I venous thrombus (Mayo Clinic classification) for robot-assisted radical nephrectomy and thrombectomy with 3D AR guidance. Five patients were prospectively enrolled; three had a level 0 thrombus and two had a level I thrombus. The mean operative time was 123 ± 15 min, mean IVC clamping time was 9.4 ± 6.8 min, and mean estimated blood loss was 750 ± 150 ml. The AR system allowed precise estimation of the thrombus location in all cases. No intraoperative complications or postoperative Clavien-Dindo grade >2 complications occurred. Use of 3D AR guidance allowed correct estimation of the limits of the thrombus and guided the surgeon in selecting an appropriate surgical strategy.

Identifiants

pubmed: 38434189
doi: 10.1016/j.euros.2024.02.003
pii: S2666-1683(24)00253-2
pmc: PMC10909593
doi:

Types de publication

Case Reports

Langues

eng

Pagination

43-46

Informations de copyright

© 2024 The Authors.

Auteurs

Daniele Amparore (D)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Enrico Checcucci (E)

Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

Federico Piramide (F)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Giovanni Busacca (G)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Gabriele Volpi (G)

Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

Sabrina De Cillis (S)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Michele Sica (M)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Paolo Verri (P)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Alberto Piana (A)

Romolo Hospital, Rocca di Neto, Italy.

Michele Di Dio (M)

Division of Urology, Department of Surgery, SS Annunziata Hospital, Cosenza, Italy.

Cristian Fiori (C)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Francesco Porpiglia (F)

Department of Oncology, Division of Urology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Classifications MeSH